Pregled bibliografske jedinice broj: 1097140
From Design to In vivo Studies of Hybrid Quinazoline-1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors
From Design to In vivo Studies of Hybrid Quinazoline-1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors // Book of Abstracts: 4th Mini Symposium for Young Scientists of the Section of Medicinal and Pharmaceutical Chemistry / Basarić, Nikola (ur.).
Zagreb: Hrvatsko kemijsko društvo, 2020. str. 11-11 (predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1097140 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
From Design to In vivo Studies of Hybrid Quinazoline-1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors
Autori
Pathak, Prateek ; Rimac, Hrvoje ; Grishina, Maria ; Verma, Amita ; Potemkin, Vladimir
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Book of Abstracts: 4th Mini Symposium for Young Scientists of the Section of Medicinal and Pharmaceutical Chemistry
/ Basarić, Nikola - Zagreb : Hrvatsko kemijsko društvo, 2020, 11-11
Skup
4th Mini Symposium for Young Scientists of the Section of Medicinal and Pharmaceutical Chemistry
Mjesto i datum
Zagreb, Hrvatska, 08.12.2020
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
EGFR inhibitors ; synthesis ; molecular modelling ; in vitro assays ; in vivo assays
Sažetak
A series of hybrid quinazoline-1, 3, 5-triazine derivatives were synthesized and their activity as EGFR inhibitors was tested using in silico (structure-activity relationship, docking, and molecular dynamics), in vitro (cytotoxicity, EGFR inhibitory activity), in ovo (antiangiogenic activity), and in vivo (effects on body weight, tumor incidence and volume, enzymatic and non-enzymatic antioxidants, biotransformation enzymes, and lipid profile level) methods. The derivatives were found to be active against different cancer and non-toxic against normal cell lines, with some compounds having a very similar profile to erlotinib, a gold standard EGFR inhibitor. The study demonstrated that the best compound (7e) has lead properties against breast cancer and can serve as a starting compound for further development of anti-EGFR compounds with a very different scaffold compared to EGFR inhibitors already present on the market.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Interdisciplinarne prirodne znanosti, Farmacija